Skip to main content

Table 4 Drug interactions with gemfibrozil

From: Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders

Concomitant medication Cautions
HMG-CoA Reductase Inhibitors risk of myopathy and rhabdomyolysis
Anticoagulants warfarin dosage should be reduced
CYP2C8 Substrates drugs metabolized CYP2C8 (e.g., dabrafenib, loperamide, montelukast, paclitaxel, pioglitazone, rosiglitazone) may be required to reduce
OATP1B1 substrates substrates of OATP1B1 (e.g., atrasentan, atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, SN-38 [active metabolite of irinotecan], rosuvastatin, pitavastatin, pravastatin, rifampin, valsartan, olmesartan) may be required to reduce
Bile Acid-Binding Resins resin-granule drugs such as colestipol (5 g) are recommended at 2 or more hours apart
Colchicine myopathy, including rhabdomyolysis in chronic administration of colchicine
  1. SPC of LOPID issued March.2016